SMURF1 promotes the proliferation, migration and invasion of gastric cancer cells

  • Authors:
    • Youmao Tao
    • Caixia Sun
    • Tao Zhang
    • Yan Song
  • View Affiliations

  • Published online on: July 17, 2017     https://doi.org/10.3892/or.2017.5825
  • Pages:1806-1814
Metrics: PDF 0 views | HTML 0 views
0

Abstract

Smad ubiquitin regulatory factor 1 (SMURF1), a well-known E3 ubiquitin ligase, targets substrate proteins for ubiquitination and proteasomal degradation. Accumulating studies have shown that SMURF1 acts as an oncogenic factor in human malignancies. However, the clinical significance of SMURF1 and its role in gastric cancer (GC) remain unclear. The expression of SMURF1 was detected in 68 cases of GC and corresponding tumor-adjacent specimens. Our results revealed that SMURF1 was prominently overexpressed in GC specimens compared to corresponding tumor-adjacent tissues. Furthermore, increased levels of SMURF1 mRNA were also observed in GC cell lines. Clinicopathological detection ascertained that SMURF1-positive expression was associated with large tumor size, more lymph nodes and distant metastasis as well as advanced tumor-node-metastasis (TNM) stage of GC. Notably, GC patients with SMURF1 positive‑expressing tumors exhibited a significant decreased survival. Further experiments illustrated that SMURF1 knockdown significantly inhibited proliferation, migration and invasion of MGC-803 cells, while SMURF1 overexpression prominently promoted these behaviors in SGC-7901 cells. In vivo studies revealed that SMURF1 knockdown markedly inhibited tumor growth and liver metastasis of GC. Mechanically, SMURF1 inversely regulated the expression of DOC-2/DAB2 interactive protein (DAB2IP) in GC tissues and cells. Furthermore, DAB2IP restoration revealed similar effects to SMURF1 knockdown on MGC-803 cells with decreased proliferation, migration and invasion. In addition, the PI3K/Akt pathway and its downstream targets including c-Myc and ZEB1 were potentially involved in the oncogenic role of the SMURF1/DABIP axis. Collectively, the present study revealed the first evidence that SMURF1 can be potentially used as a clinical biomarker and target for novel treatment of human GC.

Related Articles

Journal Cover

September 2017
Volume 38 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

2016 Impact Factor: 2.662
Ranked #31/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Tao, Y., Sun, C., Zhang, T., & Song, Y. (2017). SMURF1 promotes the proliferation, migration and invasion of gastric cancer cells. Oncology Reports, 38, 1806-1814. https://doi.org/10.3892/or.2017.5825
MLA
Tao, Y., Sun, C., Zhang, T., Song, Y."SMURF1 promotes the proliferation, migration and invasion of gastric cancer cells". Oncology Reports 38.3 (2017): 1806-1814.
Chicago
Tao, Y., Sun, C., Zhang, T., Song, Y."SMURF1 promotes the proliferation, migration and invasion of gastric cancer cells". Oncology Reports 38, no. 3 (2017): 1806-1814. https://doi.org/10.3892/or.2017.5825